Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats
- PMID: 22740878
- PMCID: PMC3362410
- DOI: 10.3892/ol.2011.442
Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats
Abstract
Cachexia is a common systemic manifestation. Additionally, myostatin is known to be a negative regulator of skeletal muscle development. The present study aimed to investigate whether formoterol down-regulates the myostatin system in skeletal muscle of tumour-bearing rats. Real-time PCR and Western blotting were used for the analysis. Results showed that rats bearing the Yoshida AH-130 ascites hepatoma, a cachexia-inducing tumour, exhibited marked muscle wasting that affected the mass of the muscles studied. The cachectic animals exhibited a significant increase in the mRNA levels of the myostatin receptor (ActIIB) in gastrocnemius muscles. Notably, the expression of the various forms of follistatin, a protein with the opposite effects to those of myostatin, was significantly reduced as a result of the implantation of the tumour. When the animals were treated with formoterol, a β-agonist with anti-cachectic potential, increases in skeletal muscle weights were observed. The β-agonist significantly increased levels of various follistatin isoforms and significantly decreased the expression levels of the myostatin receptor. In addition, formoterol treatment resulted in a significant decrease of the myostatin protein content of the gastrocnemius muscle. In conclusion, the results presented indicate that certain anabolic actions of formoterol on the skeletal muscle of cachectic animals may be mediated via the myostatin system.
Figures
Similar articles
-
Effects of the beta2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia.Biochimie. 2018 Jun;149:79-91. doi: 10.1016/j.biochi.2018.04.009. Epub 2018 Apr 12. Biochimie. 2018. PMID: 29654866
-
Muscle myostatin signalling is enhanced in experimental cancer cachexia.Eur J Clin Invest. 2008 Jul;38(7):531-8. doi: 10.1111/j.1365-2362.2008.01970.x. Eur J Clin Invest. 2008. PMID: 18578694
-
Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):57-62. doi: 10.1007/s13539-011-0018-6. Epub 2011 Feb 24. J Cachexia Sarcopenia Muscle. 2011. PMID: 21475674 Free PMC article.
-
Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia.Oncol Rep. 2008 May;19(5):1113-21. Oncol Rep. 2008. PMID: 18425366
-
Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting.Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H1973-82. doi: 10.1152/ajpheart.00200.2011. Epub 2011 Mar 18. Am J Physiol Heart Circ Physiol. 2011. PMID: 21421824 Free PMC article. Review.
Cited by
-
Cancer cachexia: molecular mechanisms and treatment strategies.J Hematol Oncol. 2023 May 22;16(1):54. doi: 10.1186/s13045-023-01454-0. J Hematol Oncol. 2023. PMID: 37217930 Free PMC article. Review.
-
Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers.Front Cell Dev Biol. 2021 Sep 14;9:719643. doi: 10.3389/fcell.2021.719643. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34595171 Free PMC article. Review.
-
Polyphenols and Their Effects on Muscle Atrophy and Muscle Health.Molecules. 2021 Aug 12;26(16):4887. doi: 10.3390/molecules26164887. Molecules. 2021. PMID: 34443483 Free PMC article. Review.
-
Muscle Wasting Diseases: Novel Targets and Treatments.Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:315-339. doi: 10.1146/annurev-pharmtox-010818-021041. Epub 2018 Aug 27. Annu Rev Pharmacol Toxicol. 2019. PMID: 30148697 Free PMC article. Review.
-
Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats.PeerJ. 2017 Dec 13;5:e4109. doi: 10.7717/peerj.4109. eCollection 2017. PeerJ. 2017. PMID: 29255650 Free PMC article.
References
-
- Harvey KB, Bothe A, Jr, Blackburn GL. Nutritional assessment and patient outcome during oncological therapy. Cancer. 1979;43:2065–2069. - PubMed
-
- Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev. 1997;17:477–498. - PubMed
-
- Argiles JM, Lopez-Soriano FJ. The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci. 1996;17:223–226. - PubMed
-
- Sanchis D, Busquets S, Alvarez B, Ricquier D, Lopez-Soriano FJ, Argiles JM. Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Lett. 1998;436:415–418. - PubMed
-
- Van Royen M, Carbo N, Busquets S, et al. DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? Biochem Biophys Res Commun. 2000;270:533–537. - PubMed